154 related articles for article (PubMed ID: 38049077)
1. Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape.
Ebrahimi S; Habibzadeh A; Khojasteh-Kaffash S; Valizadeh P; Samieefar N; Rezaei N
Crit Rev Oncol Hematol; 2024 Jan; 193():104225. PubMed ID: 38049077
[TBL] [Abstract][Full Text] [Related]
2. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
3. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
4. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
7. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
8. Widespread vitiligo and poliosis following ipilimumab-nivolumab combination therapy.
Nemovi K; Jamali A; Matinpour K; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1278-1282. PubMed ID: 36785936
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.
Pouget JP; Chan TA; Galluzzi L; Constanzo J
Trends Cancer; 2023 Nov; 9(11):968-981. PubMed ID: 37612188
[TBL] [Abstract][Full Text] [Related]
13. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
14. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
16. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies.
Bilgihan MT; Eryigit AN; Ciftciler R
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):23-31. PubMed ID: 37863681
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
19. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
